Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 1 recruiting now later-stage tilt small index

Perennial Allergic Rhinitis (PAR): later-stage trial registry

1 of 1 indexed Perennial Allergic Rhinitis (PAR) trials are currently recruiting, with more weight in Phase 3-4.

Corpus placement: #11,370 of 28,707 conditions by registered trial count.

1 US clinical trials · 1 currently recruiting · #11,370 of 28,707 conditions by registered trial count

Perennial Allergic Rhinitis (PAR): 1 US clinical trial tracked, 1 recruiting.

Perennial Allergic Rhinitis (PAR) is the subject of 1 registered US clinical trials on ClinicalTrials.gov, 1 of them currently open to new participants. 1 are in Phase 3-4 (later-stage) and 0 in Phase 1-2 (earlier-stage). The most active sponsor is Eli Lilly and Company, running 1 of these trials.

Enrollment posture brief

Registry condition perennial-allergic-rhinitis-par

OPEN 1 | RECR 100% | LATE 1 | EARLY 0 | RANK #11370 | SPON 1

Nearest open-share peer: Aortic Arch Aneurysm (100% recruiting · 5 trials)

Perennial Allergic Rhini (this)Perennial Allergic Rhini (th…100%Ablation80%ACL Reconstruction80%Abuse, Drug60%Acceptability60%
Open-enrollment share among volume-matched conditions near Perennial Allergic Rhinitis (PAR)

Perennial Allergic Rhinitis (PAR) lists 1 open slots (100% of 1 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Perennial Allergic Rhinitis (PAR) on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Perennial Allergic Rhinitis (PAR) is recruiting above its size-band peers.

    1 of 1 indexed trials (100%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

Phase 31

Phase Distribution

PhaseTrial count
Phase 3 1

Top Sponsors

Named interventions

Most-linked intervention names on Perennial Allergic Rhinitis (PAR) records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Standard therapy for INCS Drug
1 trials
LY3650150 Drug
1 trials
Placebo Drug
1 trials

US sites by state

Facility locations filed on Perennial Allergic Rhinitis (PAR) trials. A trial with sites in several states counts in each.

New York 1 trials
New Jersey 1 trials
Nebraska 1 trials
North Carolina 1 trials
Missouri 1 trials
Minnesota 1 trials
Michigan 1 trials
Kentucky 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Perennial Allergic Rhinitis (PAR) page

1 registered trials, 1 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

  • 1 Perennial Allergic Rhinitis (PAR) trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
  • Eli Lilly and Company sponsors the most Perennial Allergic Rhinitis (PAR) trials on record, review their full trial history before evaluating a specific study. See Eli Lilly and Company's trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Perennial Allergic Rhinitis (PAR) condition card totals 1 registered trials; most-linked intervention Standard therapy for INCS; top US site state New York. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.